

Corey Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6008885/publications.pdf>

Version: 2024-02-01

83
papers

3,178
citations

172457

29
h-index

175258

52
g-index

90
all docs

90
docs citations

90
times ranked

5106
citing authors

#	ARTICLE	IF	CITATIONS
1	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). BMC Infectious Diseases, 2022, 22, 70.	2.9	4
2	SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants. PLoS Pathogens, 2022, 18, e1010339.	4.7	13
3	Limited Recognition of Highly Conserved Regions of SARS-CoV-2. Microbiology Spectrum, 2022, 10, e0278021.	3.0	5
4	Humoral and cellular immune response to Sars-CoV-2 wild-type and variants of concern following 3-dose vaccination in a large cohort of adults with cancer: The SerOzNET study.. Journal of Clinical Oncology, 2022, 40, LBA12065-LBA12065.	1.6	0
5	Pretransplant Cytomegalovirus-Specific Cellular Immunity and Risk of Viral Reactivation Following Lung Transplantation: A Prospective Cohort Study. Journal of Infectious Diseases, 2021, 224, 312-317.	4.0	10
6	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends in Molecular Medicine, 2021, 27, 75-90.	6.7	5
7	Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. Clinical and Translational Immunology, 2021, 10, e1334.	3.8	5
8	Rapid whole-blood assay to detect SARS-CoV-2-specific memory T cell immunity following a single dose of AstraZeneca ChAdOx1 COVID-19 vaccine. Clinical and Translational Immunology, 2021, 10, e1326.	3.8	11
9	'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies. , 2021, 9, e001608.		7
10	The presentation of SARS-CoV-2 peptides by the common HLA-A*02:01 molecule. IScience, 2021, 24, 102096.	4.1	23
11	Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma. Npj Precision Oncology, 2021, 5, 24.	5.4	19
12	Protocol for purification and identification of MHC class I immunopeptidome from cancer cell lines. STAR Protocols, 2021, 2, 100385.	1.2	1
13	CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity, 2021, 54, 1055-1065.e5.	14.3	145
14	The role of T cell immunity in COVID-19 severity amongst people living with type II diabetes. FEBS Journal, 2021, 288, 5042-5054.	4.7	9
15	Molecular Basis of a Dominant SARS-CoV-2 Spike-Derived Epitope Presented by HLA-A*02:01 Recognised by a Public TCR. Cells, 2021, 10, 2646.	4.1	15
16	Early Cytomegalovirus Reactivation after Allogeneic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition. Blood, 2021, 138, 648-648.	1.4	0
17	Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. Journal of Experimental Medicine, 2020, 217, .	8.5	37
18	Rapid detection of SARS-CoV-2-specific memory T cell immunity in recovered COVID-19 cases. Clinical and Translational Immunology, 2020, 9, e1219.	3.8	21

#	ARTICLE	IF	CITATIONS
19	Tâ€cell adoptive immunotherapy for BK nephropathy in renal transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13399.	1.7	11
20	Proteome-wide analysis of Tâ€cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals a unique transcriptional and functional profile. <i>Clinical and Translational Immunology</i> , 2020, 9, e01102.	3.8	11
21	Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. <i>Journal of Clinical Investigation</i> , 2020, 130, 6041-6053.	8.2	37
22	Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 632-640.	5.8	72
23	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. <i>Cancer Discovery</i> , 2019, 9, 1754-1773.	9.4	173
24	Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development. <i>Expert Review of Vaccines</i> , 2019, 18, 457-474.	4.4	26
25	Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis. <i>Blood Advances</i> , 2019, 3, 1774-1777.	5.2	15
26	Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific Tâ€cell therapy. <i>Clinical and Translational Immunology</i> , 2019, 8, e01088.	3.8	10
27	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating Tâ€cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	2.3	29
28	T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response. <i>Journal of Clinical Investigation</i> , 2019, 129, 5020-5032.	8.2	14
29	Immune-based therapeutic approaches to virus-associated cancers. <i>Current Opinion in Virology</i> , 2018, 32, 24-29.	5.4	4
30	Epigenetic programming of T cells impacts immune reconstitution in hematopoietic stem cell transplant recipients. <i>Blood Advances</i> , 2018, 2, 656-668.	5.2	8
31	Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. <i>JCI Insight</i> , 2018, 3, .	5.0	105
32	Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities. <i>Expert Review of Vaccines</i> , 2017, 16, 377-390.	4.4	20
33	BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. <i>Clinical Microbiology Reviews</i> , 2017, 30, 503-528.	13.6	154
34	Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. <i>OncImmunology</i> , 2017, 6, e1273311.	4.6	41
35	Priming of transcriptional memory responses via the chromatin accessibility landscape in T cells. <i>Scientific Reports</i> , 2017, 7, 44825.	3.3	16
36	Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. <i>Immunology and Cell Biology</i> , 2017, 95, 364-371.	2.3	17

#	ARTICLE	IF	CITATIONS
37	Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 685-687.	0.6	18
38	Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16058.	4.1	15
39	Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution. <i>Journal of Virology</i> , 2016, 90, 7497-7507.	3.4	6
40	Autophagy and proteasome interconnect to coordinate cross-presentation through MHC class I pathway in B cells. <i>Immunology and Cell Biology</i> , 2016, 94, 964-974.	2.3	30
41	Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+ T cell recognition. <i>JCI Insight</i> , 2016, 1, e87102.	5.0	66
42	Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. <i>PLoS Pathogens</i> , 2016, 12, e1005799.	4.7	74
43	Cytokine-Mediated Loss of Blood Dendritic Cells During Epstein-Barr Virus-Associated Acute Infectious Mononucleosis: Implication for Immune Dysregulation. <i>Journal of Infectious Diseases</i> , 2015, 212, 1957-1961.	4.0	22
44	Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction. <i>Journal of Virology</i> , 2015, 89, 9137-9141.	3.4	21
45	Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. <i>Clinical and Translational Immunology</i> , 2015, 4, e35.	3.8	48
46	Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors. <i>Immunotherapy</i> , 2015, 7, 563-572.	2.0	8
47	<i>Ex vivo</i> expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. <i>Clinical and Translational Immunology</i> , 2015, 4, e31.	3.8	48
48	Naive CD8 ⁺ T-cell precursors display structured TCR repertoires and composite antigen-driven selection dynamics. <i>Immunology and Cell Biology</i> , 2015, 93, 625-633.	2.3	48
49	T Cell Cross-Reactivity between a Highly Immunogenic EBV Epitope and a Self-Peptide Naturally Presented by HLA-B*18:01+ Cells. <i>Journal of Immunology</i> , 2015, 194, 4668-4675.	0.8	14
50	The Development of Prophylactic and Therapeutic EBV Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 455-473.	1.1	19
51	B cell-derived circulating granzyme B is a feature of acute infectious mononucleosis. <i>Clinical and Translational Immunology</i> , 2015, 4, e38.	3.8	15
52	Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma. <i>Cancer Research</i> , 2014, 74, 3466-3476.	0.9	155
53	Phenotypic and transcriptional profile correlates with functional plasticity of antigen-specific CD4+ T cells. <i>Immunology and Cell Biology</i> , 2014, 92, 181-190.	2.3	7
54	Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1541-1544.	3.0	67

#	ARTICLE	IF	CITATIONS
55	Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1064-1077.	3.3	12
56	Molecular Imprint of Exposure to Naturally Occurring Genetic Variants of Human Cytomegalovirus on the T cell Repertoire. <i>Scientific Reports</i> , 2014, 4, 3993.	3.3	19
57	Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. <i>Expert Review of Vaccines</i> , 2013, 12, 661-676.	4.4	33
58	Nasopharyngeal Carcinoma Immunotherapy: Current Strategies and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2013, , 173-186.	1.6	0
59	EBV and nasopharyngeal carcinoma: a target for cellular therapies. <i>Immunotherapy</i> , 2013, 5, 821-824.	2.0	6
60	Essential Developmental, Genomic Stability, and Tumour Suppressor Functions of the Mouse Orthologue of hSSB1/NABP2. <i>PLoS Genetics</i> , 2013, 9, e1003298.	3.5	28
61	Epstein-Barr virus-associated malignancies: pathobiology and emerging therapeutic options. <i>Microbiology Australia</i> , 2013, 34, 120.	0.4	1
62	Cellular immune therapy for viral infections in transplant patients. <i>Indian Journal of Medical Research</i> , 2013, 138, 796-807.	1.0	9
63	Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1116-1125.	0.9	159
64	The Impact of a Large and Frequent Deletion in the Human TCR Î² Locus on Antiviral Immunity. <i>Journal of Immunology</i> , 2012, 188, 2742-2748.	0.8	36
65	A new approach for cellular immunotherapy of nasopharyngeal carcinoma. <i>Oncolmmunology</i> , 2012, 1, 1440-1442.	4.6	12
66	Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. <i>Blood</i> , 2012, 120, 3237-3245.	1.4	25
67	Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T cells in patients with glioblastoma multiforme. <i>Immunology and Cell Biology</i> , 2012, 90, 872-880.	2.3	66
68	Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. <i>Journal of General Virology</i> , 2011, 92, 1021-1031.	2.9	30
69	Differential Outcome of IL-2/Anti-IL-2 Complex Therapy on Effector and Memory CD8+ T Cells following Vaccination with an Adenoviral Vector Encoding EBV Epitopes. <i>Journal of Immunology</i> , 2011, 186, 5784-5790.	0.8	7
70	Herpesvirus vaccines: Challenges and future prospects. <i>Hum Vaccin</i> , 2010, 6, 1062-1067.	2.4	7
71	Generation of Cytotoxic T Lymphocytes for Immunotherapy of EBV-Associated Malignancies. <i>Methods in Molecular Biology</i> , 2010, 651, 49-59.	0.9	6
72	Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8 ⁺ T Cells Correlates with Increased Resistance to Galectin-1-Mediated Suppression. <i>Journal of Virology</i> , 2009, 83, 6192-6198.	3.4	51

#	ARTICLE	IF	CITATIONS
73	Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. <i>Blood</i> , 2009, 113, 6148-6152.	1.4	47
74	Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. <i>Blood</i> , 2009, 114, 2244-2253.	1.4	61
75	Generating functional CD8 ⁺ T cell memory response under transient CD4 ⁺ T cell deficiency: Implications for vaccination of immunocompromised individuals. <i>European Journal of Immunology</i> , 2008, 38, 1857-1866.	2.9	12
76	Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9319-9324.	7.1	66
77	Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human Cytomegalovirus. <i>PLoS ONE</i> , 2008, 3, e3256.	2.5	37
78	Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 1326-1329.	1.4	145
79	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. <i>Blood</i> , 2006, 108, 2280-2289.	1.4	215
80	Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope. <i>Journal of Immunology</i> , 2006, 177, 4897-4906.	0.8	63
81	Synergism between active listeriolysin O and dimethyldioctadecylammonium bromide to activate CD8+ T cells. <i>Vaccine</i> , 2005, 23, 4481-4488.	3.8	3
82	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15440-15445.	7.1	226
83	Pre-Existing Cellular Immunity to SARS-CoV-2 Through an Immunodominant Epitope. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2